Clinical successes related to the vascular endothelial growth factor (VEGF) receptor have come in the form of blockers, such as Genentech's Avastin (bevacizumab). By blocking blood vessel growth, VEGF receptor blockers starve tumor growth Read More
LONDON – Drug delivery specialist Lipoxen plc is selling a majority, £12.8 million (US$20.9 million), stake in the company to SynBio LLC, a firm that is majority-owned by the government of Russia, as one of a series of moves to transform itself into a mainstream drug developer. Read More
Allos Therapeutics Inc., of Westminster, Colo., reported that second quarter net sales of peripheral T-cell lymphoma drug Folotyn (pralatrexate) increased 39 percent to $11 million compared to $7.9 million for the same quarter in 2010. Read More
MolMed SpA, of Milan, Italy, signed an agreement with GlaxoSmithKline plc, of London, and will develop a production process for an investigational gene therapy for adenosine deaminase deficiency-severe combined immune deficiency, a rare, life-threatening disease that affects approximately 350 children worldwide. MolMed said it will receive as much as $7.78 million in revenue over a two-year period. Read More
Trius Therapeutics Inc., of San Diego, reached an agreement with the FDA, under the special protocol assessment (SPA) process, on the design of its second planned Phase III study for the intravenous and oral dosage forms of torezolid phosphate to treat acute bacterial skin and skin structure infections. Read More
Scientists from the Italian G. d'Annunzio University, in Chieta, reported this week that not all atherosclerotic plaque is created equal in terms of the stroke risk it poses. Read More
Amylin Pharmaceuticals Inc. and partner Takeda Pharmaceutical Co. Ltd. have discontinued development of combination obesity candidate pramlintide/metreleptin after what they described as a "commercial reassessment" of a revised development plan and the "evolving dynamics" of obesity therapeutics. Read More
WASHINGTON – Fears that the FDA and National Institutes of Health (NIH) may loosen researchers' collars on conflicts of interest have government watchdogs nipping at their heels. Read More
